

**9 Months Report 2008/2009**

**9 Monatsbericht 2008/2009**

**Discover a Healthy Future**



**bio  
LITEC**

## **Contents**

<b>biolitec at a glance</b>	<b>3</b>
<b>I Preface CEO</b>	<b>4</b>
<b>II The Company</b>	<b>6</b>
<b>III Management Report</b>	<b>10</b>
<b>IV Financial Statement</b>	<b>27</b>
<b>V Notes</b>	<b>33</b>

## biolitec at a glance

		31.03.2009	31.03.2008
		T €	T €
Total assets	Bilanzsumme	65.499	63.505
Revenues	Umsatzerlöse	23.278	28.045
Gross profit	Bruttoergebnis	16.158	19.399
EBIT	EBIT	- 701	4.232
Net income / loss	Überschuss / Verlust	- 140	3.521
Net income per share (€)	Ergebnis je Aktie (€)	- 0,01	0,33
Employees (average)	Mitarbeiter (durchschnittliche Anzahl)	225	240
EBIT w/o R&D costs	EBIT ohne F&E Kosten	2.791	7.846
Net income / loss w/o R&D costs	Überschuss / Verlust ohne F&E Kosten	3.352	7.135
Net income per share w/o R&D (€)	Ergebnis je Aktie ohne F&E Kosten (€)	0,32	0,68

## I. Preface CEO

Dear shareholders, dear business partners,

While the economy weakened further, particularly in the USA, biolitec's strategy of diversifying and strengthening its global presence pays off. While a comparison of performance with the corresponding last year's numbers shows declines, we need to consider the large BPH mobile provider contract that did not get repeated. Also compared with 06/07 (that led up to a record year for the company) this year's numbers look quite reasonable.



The company's products are the most innovative on the market and even our major aesthetic product line (ELVeS™PainLess) is a reimbursable procedure in the USA – and reimbursement is of key interest there in the increasingly difficult economic environment where people cut back discretionary spending. For the urology BPH line the outlook in the US has brightened up, as the long delayed “Stark laws” are set to be implemented resulting in increased office-procedure interest. The AUA (American Urological Association) congress in Chicago showed remarkable interest from North, but also South America.

Our investment in areas such as Dubai, South America and Asia is paying off with sales increases from these regions that are far from saturated. And our problem area - Foscan® cancer treatment – is getting off to a good start with the Bracco deal finalized and renewed expressions of interest from other pharma companies. This will relieve the group from several million of profit transfer and investment requirements into its pharma business from the medical device side in the coming years. The licensing partners contractually have to contribute substantial amounts to clinical research and development.

Inventory levels will be reduced in the coming quarters due to the reduced staff levels in production freeing up working capital for acquisition opportunities that might arise.

The company has made substantial efforts to convert its equipment base to RFID locked systems to assure disposable sales and provide safer and healthier procedures.

The technological progress on the laser side and fiber side - a new side firing device (the twister) and new higher powered laser models - was well received at EAU (European Association of Urology) and AUA (American Urological Association). In line with these new developments we have undertaken some write down of our inventory levels for older units.

Overall medical reimbursed procedures represent one of the safest and most stable business environments in uncertain times and our focus on per procedure revenue generation through disposable sales and pharma sales fits the current environment.

While cost reduction measures were taken, they have only started to show their impact. Nevertheless last quarter's operating income was near breakeven (- 48 TEUR).

We have made good progress in the litigations in the USA. The positive settlement of the litigation with Fortec – our largest mobile customer in the USA, results in future upside potential for urology sales in the market.

Despite the negative result for the nine month period we should further improve in the current quarter leading to relatively small losses for the year in total.

Biolitec's share value and market cap unfortunately still does not reflect its true potential. A US competitor in the minimal invasive vein treatment market was recently sold at approximately 4.4 times turn over – by this measure our share should have an upside potential of approximately 350%.

Dr. Stefan Spaniol's contract as Member of the Board of Directors, responsible for Research and Development, has expired in March 2009. He is now concentrating his activities on the worldwide improvement of productivity of the Biolitec group.

I wish to thank our customers, employees and business partners for their confidence in our products and our company.

Yours,

Dr. Wolfgang Neuberger

(CEO)

## II. The Company

### The biolitec Group

biolitec is the technology leader in diode lasers, fiber optic disposables and photodynamic drugs. The company is the only supplier for photodynamic therapy worldwide that offers all relevant core competencies – photosensitizers, lasers and optical fibers as well as an approved cancer drug (Foscan<sup>®</sup>) including the active substance Temoporfin<sup>®</sup>. The combination of medical technology and drug development for diverse medical indications is an outstanding feature of biolitec. Lasers and the pertinent disposables represent the medtech area responsible for biolitec's turnover and earning power and dynamic growth opportunities, Temoporfin<sup>®</sup> as an active substance and Foscan<sup>®</sup> as a drug represent the biotech area and a further future upside potential.

biolitec is globally present in all relevant core markets with its broad range of lasers and fiber optic products.

The current growth and innovation emphasis of biolitec is on minimally invasive therapies (BPH treatment, haemorrhoids) and aesthetics (ELVeS<sup>™</sup> PainLess) with a strong focus on re-establishing the patient's quality of life. A further emphasis of our efforts is to obtain reimbursement for the procedures on a country by country basis.

### Aesthetics

People want the confidence of knowing that they are getting the highest quality care and treatment options without long absenteeism from work. Cost and workload pressure on patients increase the demand for ambulant, minimally invasive treatment methods. Furthermore, the market for aesthetics - comprising of vein treatments to laser body contouring - is driven by an increase in discretionary income of aging baby-boomers, who place a premium on good health and personal appearance, and have demonstrated a willingness to pay for health and cosmetic products.

While purely discretionary spending in the USA is currently taking a dip, reimbursed procedures (veins) are increasingly attractive to doctors. In other countries most spending is private and growth for discretionary aesthetic procedures like LipoForm<sup>™</sup> is expected.

The advantages of minimally invasive treatments are outstanding: short times of recovery, minimal side effects, cost saving. Our laser based treatments enable us to satisfy the growing demand for minimally invasive treatments.

With our body contouring procedures we offer a system for aesthetic and cosmetic applications – from cellulite therapy to laser assisted liposuction – using laser and light technology.

The LipoForm™ platform enables both, laser assisted liposuction for patients suffering from adiposity as well as laser lipolysis allowing more delicate aesthetic treatments e.g. in the facial region.

LipoForm™ quickly liquefies fat cells, improves appearance and spares healthy surrounding tissue in less time than any other laser on the market. It features dual absorption in water and hemoglobin, hence causing blood vessels to coagulate immediately, resulting in less bleeding, swelling and bruising. It is virtually pain-free with little to no side effects and downtime and offers patients' unsurpassed aesthetic outcomes.

### **ELVES® .... The future is radial**

Diseases of veins are one of the most widespread conditions today. Up to 40% of women and 20% of men suffer from symptoms such as tiredness and swelling of the legs. Based on the experience gathered with the most frequently used laser system worldwide for the treatment of venous insufficiency, the clinically proven ELVeS® Endo Laser Vein System has been continuously enhanced leading to the development of ELVeS® PainLess and ELVeS® RADIAL.

ELVeS® PainLess is a versatile and easy to use system for minimally invasive treatment of various forms of varicose veins. The combination of the special wavelength of the ELVeS® PainLess and the radial emission of the ELVeS® Radial fiber enables high efficiency and maximum patient comfort.

The procedure can be performed without tumescence eliminating cosmetically undesirable injection marks and providing substantial time savings. The ELVeS™ RADIAL fiber applies the energy faster and more targeted than any other available fiber in the endovenous market. It guarantees safe closure of the vein and eliminates perforation and charring due to its homogenous circumferential (360°) energy emission.

### **Photodynamic therapy with Foscan®**

biolitec is a global leader in medical laser applications and photodynamic therapy. The Foscan® photodynamic therapy offers patients an innovative and gentle form of tumour therapy resulting in very good functional and cosmetic results significantly improving their quality of life. Foscan® is already EMEA approved as a palliative drug to treat head and neck cancer. Head and neck cancer is the term given to a variety of malignant tumours that develop in the mouth, the throat, the nasal cavity and the larynx. Most head and neck cancers are squamous cell carcinomas.

Major milestones of Foscan® include the successful completion of the confirmatory study end of 2007, the approval of an additional strength of Foscan® vials to cover

new indications, the approval of Foscan<sup>®</sup> in further markets (Argentina; Colombia/ Mexico expected soon) as well as distribution contracts with major leading pharmaceutical companies in Latin America and Italy (Bracco), including major clinical study commitments and contributions. Under the agreement over the next five years at least 11 million will be spent by Bracco for products purchases and clinical studies in a rather even split. Recently other pharma companies indicated the interest in Foscan<sup>®</sup> for specific regional markets.

Besides this, Foscan<sup>®</sup> recently achieved the reimbursement in the Netherlands. Six medical research and treatment centers as the NKI-AVL (Netherlands Cancer Institute), clinics in Groningen, Rotterdam, Utrecht, Leiden and Amsterdam are already using the drug to treat patients with head and neck cancer. German patients now can also opt to receive in-patient treatment (with a hospital stay) in the Netherlands and apply to have the cost of medication covered by their health insurance funds. This option may be particularly attractive to German patients living near the Dutch border. The application and development for Foscan<sup>®</sup> in Nasopharyngeal Cancer is supported by biolitec for the Indonesian and Malaysian market; with southern China a further interesting region for this indication. Currently Foscan<sup>®</sup> is used in more than 30 clinics throughout Europe. To date, several thousand patients have been treated with Foscan<sup>®</sup>. The major treatment centre in London treated approximately thousand patients to date.

### **Minimally invasive Laser Medicine - BPH**

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland restricting the urinary flow from the bladder. It is one of the most common diseases affecting men. Nearly 50% of men over 50 and 80% of men over 80 develop the obstructive urinary symptoms associated with BPH.

LIFE<sup>™</sup> (Laser Induced Flow Enhancement) laser therapy with the EVOLVE<sup>®</sup> laser system for the treatment of BPH has already become established as a standard treatment in the USA and Germany, and is covered by compulsory health insurance funds. The new EVOLVE<sup>®</sup> 300, the world's most powerful medical diode laser, provides urologists with a whole new level of laser power for fast and effective vaporization of prostate tissue.

From the patient's perspective, the EVOLVE<sup>®</sup> laser system offers a gentle therapy with a minimum of complications. The benefits consist in faster healing, reduced scarring, and shorter recovery times hence increasing the patients satisfaction.

At this year's EAU annual meeting in Stockholm, biolitec also showed its new EVOLVE<sup>®</sup> DUAL, the world's first medical diode laser with two different wavelengths that can be used in parallel. The EVOLVE<sup>®</sup> DUAL guarantees optimal ablation as well as the proven coagulation properties of the EVOLVE<sup>™</sup> series, which is already used for multidisciplinary applications in many clinics. EVOLVE<sup>®</sup> laser systems were

developed for a broad range of applications, including ENT medicine, gynecology, gastroenterology, pneumology, treatment of inter-vertebral disks, aesthetics and proctology.

A new side firing device the "twister" was introduced and a highlight of the AUA in Chicago. It provides the urologist with a durable versatile device that enhances the effectiveness of the laser source, simplifies handling and speed substantially and is a unique patent protected biolitec product. It is paced to become the fiber of choice for BPH and biolitec is the only company offering this patented and patent pending device.

### **HeLP™ – a new painless outpatient technique for treating haemorrhoids**

With nearly 50% of the population over 50 years suffering from the typical symptoms associated with haemorrhoids, they are the most frequently found pathology in adult population. Haemorrhoids belong to the most common diseases of the large intestine. They are pathological enlargements of the smaller vessels located beneath the mucous membrane of the large intestine.

HeLP™ (Haemorrhoid Laser Procedure) haemorrhoidal dematerialization is a minimally invasive, safe procedure (patents applied by biolitec): Using disposable guidance probes, selective laser energy and fiber optic delivery systems, which identify the haemorrhoidal arteries and produce photocoagulation and retraction of surrounding tissue.

It is surely the simplest and most effective amongst the existing techniques causing minimal pain or discomfort to the patient. Post operative recovery is faster than alternative approaches, with only few complications. Patients can go back home a few hours after the treatment and can quickly return to normal activities.

HeLP™ is the only surgical procedure that can be carried out without anesthesia. Hence it can be effectively done in day surgery or in a doctor's office setting.


### III. Management Report

#### Investor Relations


The biolitec share on January 2, 2009 started on a price level of € 3.30. In the course of the third quarter of 2008/2009 the share price decreased to a low of € 2,29, but could gain ground again at the end of the reference period. At March 31, 2009 the value of the biolitec share reached € 3,18. The market situation in the reference period was characterized by a tense market, which hit all the shares throughout the different segments. The German Share Index has reached its lowest level at the end of the quarter in March 2009 and therefore pulled down many stocks to an all-time low. Some investors make use of this fact and enter into oversold values again like biolitec, which is traditionally undervalued and provided an extremely attractive entry level price in the third quarter 2008/2009.

The biolitec share, which is listed in the Gex<sup>®</sup>-index since the beginning of 2008 (all owner-managed companies that are represented in the prime-standard and whose IPO is dated back no longer than ten years) could exceed the Prime Pharma & Healthcare Index with its performance at the end of the third quarter 2008/2009.. A US competitor (VNUS) in the minimal invasive vein treatment segment was recently sold for 4.4 times turnover – if such a measure were applied to biolitec's share in upsided potential of approximately 350 % would exist for biolitec share price from the present level.

#### Share Price Development



## Shareholder Structure (March 31, 2009)



## Investor Relations

At biolitec, high priority is placed on communication with institutional and private investors. Accordingly, investor relations activities were maintained at a significant level. Current information about biolitec, such as financial reports, press releases, ad hoc announcements and the financial calendar can be retrieved from our website [www.biolitec.com](http://www.biolitec.com). Moreover biolitec addresses the public as well as its shareholders via the media. biolitec is scheduled to participate in several conferences and congresses where customers, interested investors and analysts will have the opportunity to get detailed information about the situation, the goals and strategy of the company.

### Important events in the third quarter 08/09:

biolitec AG signed a settlement agreement for the lawsuit with its largest mobile customer in the USA in March. The settlement involved payment of all outstanding fibre receivables as well as partial returns, partial payments and partial upgrades of the customers' laser base. The dispute arose due to alleged breach of verbal agreements and disagreements over payments. Both companies see substantial opportunities in the BPH treatment market in the USA, going forward.

Also in March biolitec scored a mayor victory in the United States District Court for the District of Massachusetts against American Medical Systems (AMS). The court found the biolitec LIFE (Laser Induced Flow Enhancement) method and Evolve (diode) laser not to infringe.

In March and April 2009 biolitec participated at the world's largest urology congresses of the EAU (European Association of Urology) in Stockholm and AUA (American Urological Association) in Chicago. Biolitec mainly presented the

innovative products LIFE™ and Twister® for BPH. The proctology congress in Buenos Aires highlighted the progress achieved with biolitec's HeLP™ Hemorrhoid treatment and treatment kit that eliminates this highly prevalent problem in the minimal invasive ambulatory procedure.

At the end of the third quarter 08/09 biolitec was positively rated by analysts of RedHerring after publishing the semiannual figures. In the study RedHerring appraised the fair value of the share at 4,20 € to 4,70 €.

#### **Key Data third quarter 2008/2009 from 02/01/2009 – 31/03/2009**

Share price - high (Xetra)	3,60 €
Share price - low (Xetra)	2,29 €
Market capitalisation (Xetra, 31.03.2009)	33.44 Mio. €
Amount of shares	10,515,750 shares
ISIN	DE0005213409

## **General Economic and Business Sector Environment**

The world economy declined, primarily due to global consumer/customer uncertainty resulting from the worsening banking crisis, inventory reduction and credit supply cuts. The financial crisis increasingly affected real economies. The laser market is also influenced by global economic trends, as lasers and laser systems represent substantial investments on the part of customers whose revenues and capital budget are impacted by general economic conditions.

The market for medical laser systems is strongly segmented into applications and medical fields; a dominant competitor does not exist. The USA used to be the largest market by far (62%) for medical lasers followed by Europe (23%) and Asia (15%). Diode lasers constitute a small but growing part of this market.

An increasing awareness for a healthy way of living as well as an expanding wellness market will drive the market for healthcare products. Especially products offering greater effectiveness and convenience as well as cost saving potential are highly demanded. In the long term sales of our products will benefit from this trend to minimally invasive technology and growth in aesthetics. Continuously increasing the installed laser base will provide a solid foundation for growth in the next business years.

With its three business segments aesthetics, minimally invasive laser medicine and PDT oncology biolitec AG is a player in the medtech as well as the biotech/pharma field.

While discretionary aesthetic spending is taking a hit in the USA, other world markets are growing well (parts of Asia, Arabic countries) and the company's focus on disposable medical accessories (fibre optics) used primarily for reimbursed and non-discretionary medical treatments cushions the effect of the economic situation. The company's product line is modern and cost effective for the user.

## **Business Development**

Although the economic outlook worsened and the crisis continues biolitec's strategy of diversifying and strengthening its global presence pays off. Consolidated revenues of the third quarter 2008/2009 amounted to € 7.8 million. This represents a relatively smaller decline (12%) compared to last year's number than recorded in earlier quarters.

Compared to the 9 months period of the corresponding last year a decrease of 17% was recorded. With € 16.16 million gross profit was below last year's value (€ 19.4 million). In the first nine months of 2008/2009 biolitec achieved an EBIT of € -0.7 million hence falling far behind last year's value. The corresponding period of 08/09 was unusual (in retrospect), however, as the large mobilizer orders in the USA faltered soon after due to the delays in the legislation intended to limit LLC's (doctor's owned rental groups).

The laser segment posted revenue of € 6.5 million corresponding to a decline of 31% compared to 9 months of the previous year. The fiber optics and laser probes segment contributed € 15.57 million to the group's total revenue (previous year: € 17.3 million). Mainstays of sales are the LIFE™ BPH laser treatment and the Endoluminal Laser Treatment of Veins (ELVeS™). By launching new, innovative products in established markets and by geographical expansion, biolitec has been able to establish more key reference and training centres worldwide with a high multiplication effect. Thanks to our successful new developments we can meet the challenges of the coming quarters and further exploit the excellent potential of our product program.

## Sales and Earnings Performance

### Earnings Performance by Product Groups for the First 9 Months of 2008/2009

In the first 9 months of 2008/2009, the laser segment contributed to total sales with € 6.5 million. The decline of 31% reflects essentially the (in retrospect) atypical order shipment to mobilizers in the USA in 07/08.

Sales of disposables, such as fiber optics and laser probes, decreased in the first 9 months of the business year 2008/2009 by 10% to € 15.6 million essentially for similar reasons. The company's efforts of converting its equipments base to RFID locked systems will assure disposable sales in the future.

The pharma segment posted 9 months revenue of € 1.2 million. The company expects that the new pharma marketing partners (e.g. Bracco) as well as the recently achieved reimbursements in the Netherlands, the unconditional reimbursement in Italy as well as expected further approvals and reimbursements will make a significant difference in the future.

#### Revenue breakdown Aufgliederung der Erlöse

Product Groups	Produktgruppen	2008/2009 T€	9 Months / 9 Monate Change/Veränderung	2007/2008 T€
Fiber Optics / Laser Probes	Lichtwellenleiter/Lasersonden	15.565	-10%	17.300
Lasers	Laser	6.499	-31%	9.397
Pharma	Pharma	1.214	-10%	1.349
Sum	Summe	23.278	-17%	28.046

Product Groups	Produktgruppen	2008/2009 T€	3rd Quarter / 3. Quartal Change/Veränderung	2007/2008 T€
Fiber Optics / Laser Probes	Lichtwellenleiter/Lasersonden	5.473	0%	5.448
Lasers	Laser	1.851	-37%	2.916
Pharma	Pharma	497	-9%	549
Sum	Summe	7.821	-12%	8.913

## Earnings Performance by Regions for the First 9 Months of 2008/2009

Europe and North America accounted for the major part of the groups revenues, whereof North American sales contributed 36% to overall sales. With € 8.4 million sales in the North American region declined as the shipments to mobilizers in 07/08 included an (unusually) big order. However, the outlook in the USA has brightened up again, as the long delayed Stark laws are set to be implemented resulting in increased office-procedure interest.

Sales in the European segment amounted to € 11.9 million (previous year: € 12.8 million).

Showing a growth of 38 % Asia and rest of the world's contribution to overall sales is with € 3 million comparatively small. Nonetheless, the recently established subsidiaries are expected to lead to significantly increased sales in the future as these areas are far from reaching maturity levels.

### Revenue breakdown Aufgliederung der Erlöse

Regions	Regionen	2008/2009 T€	9 Months / 9 Monate Change/Veränderung	2007/2008 T€
Europe	Europa	11.933	-7%	12.832
North America	Nordamerika	8.390	-36%	13.067
Asia and Rest of World	Asien und Rest der Welt	2.955	38%	2.147
Sum	Summe	<b>23.278</b>	-17%	<b>28.046</b>

Regions	Regionen	2008/2009 T€	3rd Quarter / 3. Quartal Change/Veränderung	2007/2008 T€
Europe	Europa	3.814	-19%	4.699
North America	Nordamerika	2.973	-12%	3.393
Asia and Rest of World	Asien und Rest der Welt	1.034	26%	821
Sum	Summe	<b>7.821</b>	-12%	<b>8.913</b>

## Profit and Profitability for the First 9 Months of 2008/2009

In the first 9 months of the business year 2008/2009 biolitec AG achieved an EBIT (earnings before interest and taxes) of € - 0.7 million (previous year: € 3.2 million). The development of EBIT was negatively affected by the decrease in sales which in turn was impacted by the weakening of the US economy in general and by the big order shipments in 07/08. A one-time effect of writing down inventory of older units due to the technological progress the company made and redundancy payments further impacted the bottom line. Hence also the EBIT margin decreased to - 3% (previous year: 11%).

Due to the decline in sales, gross profit decreased to € 16.2 million, amounting to 69 % of consolidated revenue. The selling costs in proportion to consolidated revenues are 43% reflecting our continued investment in sales and marketing and the push into new regional markets.

The decrease in gross margin reflects the impact of the one-time write down in inventory value as a result of the technical progress achieved. Hence it is not attributable to any margin erosion in the company's business.

R&D expenses were maintained at a significant level, to ensure the groups long term growth.

EBIT in the third Quarter 2008/2009 was € – 0.1 mio. thus showing a considerable improvement of the second quarter (€ - 1.1 mio).

The company expects to make only a small loss in the full fiscal year of 2008/2009.

Key Data	€millions
Revenues	23.3
Cost of Revenues	7.1
Gross Profit	16.2
Operating Income	-0.6
EBIT	-0.7
EBIT w / o R&D costs	2.8
Net income	-0.1
Net income w / o R&D costs	3.4

## **Cash Flow**

For operating activities € - 3.2 million of cash was used.

With € - 1.4 million (last year: € - 1.7 million) less cash was used for investing activities in comparison to the previous year.

Cash out for financing activities amounted to € – 0.6 million in the period under review.

At the end of March 2009 cash and cash equivalents amounted to € 5.1 million.

Going forward the measures undertaken (reducing staff levels in production and reducing production volume in general) will significantly reduce the high inventory levels and generate cash.

The company is also expecting that the net transfer of resources to the pharma side of the business that has been persistent in the last five years will be significantly reduced going forward due to the reimbursements attained (and to be attained) for Foscan<sup>®</sup> as well as the signed distribution/licensing agreements.

Overall significantly less of the company's cash will thus flow into R&D going forward without compromising the excellent technological leadership position.

## **Financial Position**

Compared to June 30, 2008, total assets slightly decreased by € 1.1 million or respectively by 1.7%. The increase in inventories (+ € 1.65 million) is an overshoot due to the unexpected drop in demand in the USA for BPH treatment. Compared to the 6 month period inventory level shows a small decrease of € 0.2 million. Partially it is also an effect of the resurging dollar. The equipment is, after some upgrading to RFID and write downs, up-to-date and the most modern of its kind however and will be sold and placed in the coming quarters.

Inventory levels will be reduced in the coming quarters, as the production capacities and staff level are being adapted to the current demand and inventory, freeing up working capital.

Trade account receivables decreased by € 1.5 million compared to December 31, 2008.

Stockholders' equity stayed with € 54 million on March 31, 2009 at a comfortably high level .The group's equity ratio is 82%.

## **Workforce**

biolitec's employees work together to continuously increase the company's market position by unique products and quality services.

In the 9 months of the business year 2008/2009, biolitec employed on average a workforce of 225 people worldwide.

Furthermore biolitec maintains intensive communication and cooperation with universities and scientific institutes. In this context biolitec offers regularly trainee positions and diploma thesis for laser technology and related application fields.

The target is to maintain and further develop our highly qualified employees to guarantee and increase the high quality standard and the technology leadership.

## Research and Development

The medtech/biotech industry is characterized by its high innovative power which is reflected by high expenditures for research and development. German medtech companies invest on average 9% of sales in research and development of new products. In the period under review biolitec's expenditures for research and development amounted to € 3.5 million (15% of sales).

In the coming periods this amount should be reduced without compromising progress as the contracts with the new pharma partners establish the basis for substantial contributions from them.

At the end of the third quarter 2008/2009, 29 persons were employed in biolitec's research and development department. Beyond this biolitec employs a number of freelancers as well as consultants.

biolitec focuses its research and development activities on the development of new, minimally invasive treatment methods as well as their enhancement with new safety features, and the development of new products based on available core technologies. Moreover, new formulations of our photodynamic drug Temoporfin® are being tested in several applications and new PDT drugs for antibacterial applications are being developed.

In a study funded by the European Union - in cooperation with the Lund University Hospital in Lund (Sweden) - for the treatment of the Basalioma with a formulation of gel based Temoporfin®, the effectiveness and compatibility of the topical application are examined. The scientists and physicians report excellent results, which are to be supported in larger studies.

Besides this Lipomas (benign tumors of the fatty tissue) and lipodystrophy could be successfully treated using locally injected small amounts of Temoporfin®. The effectiveness of our procedure for minimally invasive removal of lipomas in lipodystrophy is to be validated in studies in Argentina. The results of the clinical study could form the basis for a possible FDA approval for lipodystrophy. Formal clinical approval studies for cellulite could follow.

For the first time one of biolitec's research projects successfully managed to reduce visceral fat (visceral fat adsorbs in the abdominal cavity by surrounding the viscera, abdominal fat tissue) in an animal model. The selective, minimally invasive therapy of the visceral fat tissue based on light and the injected biolitec drug Temoporfin® lead to a reduction in weight of about 10% on average swiftly after a singular treatment. biolitec AG plans to extend the development work to develop a clinical application used in patients in the next two or three years.

Development goals for Foscan® include inter alia treatments of cholangioma and prostate carcinoma. Foscan® is used in a clinical study on the treatment of localized prostate carcinoma initiated by the research partner, SpectraCure AB, Lund,

Sweden. For the use of interstitial activation (i.e. laser illumination of the tumor as well as of the drug from the inside out) SpectraCure has developed a device working with real-time dosimetry. The study is a phase I/II study examining the effectiveness and tolerance of a photodynamic therapy for localized prostate carcinoma.

CeramOptec GmbH, a hundred percent subsidiary of biolitec AG, develops new optical fibers, connectors, and medical laser systems. Besides the development of customized products such as e.g. fiber bundles for environmental analytics, the company takes active part in a number of publicly funded research projects in national, European, and international frameworks.

The trend in the area of industrial laser applications requires the development of high-power lasers with higher optical output powers and better beam quality. Especially for industrial laser material processing (welding and cutting), e.g. in the automotive industry or shipbuilding, high laser power (multi-kW range) combined with excellent beam quality is needed. Good beam quality and high optical power allow for precise and fast processing of work pieces, even with a high material thickness.

So far, only multi-mode fibers were used for laser beam delivery. These are sufficient for existing laser sources but would yield a loss of beam quality with the new high-brightness high-power lasers. The new laser sources with excellent beam quality necessitated the development of large-mode-area fibers (LMA fibers) for laser beam delivery, which are due to their characteristics (large core diameter of the fiber of 20  $\mu\text{m}$ , small numerical aperture  $\text{NA} \leq .0.6$ ) feasible to simultaneously deliver high optical power and preserve beam quality.

CeramOptec GmbH develops in the framework of its research projects inter alia optical fibers for generating (active optical fibers for high power fiber laser) and delivering (e.g. LMA fibers) high optical powers at high brightness. It recently developed quadratic core fibers for high performance printing lasers and dermatology lasers.

Additional research and development activities explore new light sources, in particular lamps, LEDs and diode lasers, for medical applications.

biolitec's quality management system is in accordance with the actual medical directives of the EU. Therefore risk exposures during the development phase and afterwards are believed to be well managed and kept to a minimum.

biolitec's medical device companies regularly pass successfully the audits by the relevant notified bodies.

biolitec plans to invest an above-average amount of revenues into the future oriented development of high margin systems and substances to increase our market shares in our traditional applications and open up new application fields.

Other income was recorded higher due to project progress shifts encountered for some reimbursed projects.

The change in the balance sheet position Intellectual property reflects the progress achieved in product development.

## **Opportunities and Risks**

With regard to existing opportunities and risks, we refer to the statements made in our Annual Report 2007/2008.

### **Litigation Cases**

Concerning the QLT case previously described in the 2006/2007 annual report, the Company received the payment awarded to it, from QLT, in July 2008.

There was a recent favorable ruling in the June 2007 AMS litigation, previously described in the 2006/2007 annual report. In July 2008, the United States District Court for the District of Massachusetts issued a claim construction ruling on United States Patent No. 6,986,764. In October 2008, the Company filed a motion for summary judgment of non-infringement. The Summary Judgment Hearing was postponed from December to January due to weather. It has recently been done. The Company was found not to infringe.

The litigation with Fortec was settled by a compromise and the settlement should help the company to enhance its position in the USA BPH market in the future.

The Company continues to vigorously defend itself in the ongoing litigations with VNUS, AMS and Angiodynamics, as previously described in the annual report.

In June 2008, VNUS announced a settlement in its patent litigation against Angiodynamics. In July 2008, VNUS filed a complaint against biolitec, Inc., Dornier MedTech America, Inc., and New Start Lasers, Inc. d/b/a CoolTouch, Inc. in the United States District Court for the Northern District of California. VNUS alleges among other claims, infringement of United States Patent No. 6,752,803 (“the ‘803 patent”), infringement of United States Patent No. 6,769,433 (“the ‘433 patent”), and infringement of United States Patent No. 6,258,084 (“the ‘084 patent”). The Company subsequently filed a complaint against VNUS in the United States District Court for the District of Massachusetts, seeking a declaratory judgement of patent non-infringement and invalidity against United States Patent No. 7,396,355 (“the ‘355 patent”). VNUS amended their California complaint to include the ‘355 patent. Depositions of the companies in suit have begun. The Company intends to defend this case vigorously and believes the claim to be without basis.

In March 2008, AMS and Laserscope filed a second complaint against biolitec, Inc., et al., in the United States District Court for the District of Massachusetts alleging, among other claims, infringement of United States Patent No. 5,428,699 (“the ‘699 patent”). Work on this case continues. The Company continues to defend this case vigorously and believes the claims to be without basis.

The third lawsuit already described earlier is the one with Angiodynamics. In this case Angiodynamics seeks financial coverage/recompensation from biolitec for

patent infringement claims by Diomed and VNUS, while biolitec asks for the return of funds already spent on Angiodynamics' defense. A certain potential litigation and financial risk is difficult to quantify at present. No financial reserve has been set up. No significant change from Q1. In September 2008, the United States District Court for the District of Massachusetts allowed Defendant's motion to transfer the pending Massachusetts case to the Northern District of New York. The Company will continue defend this case vigorously in the United States District Court for the Northern District of New York and believes the claim to be without basis.

In parallel to the litigations, biolitec is continuously exploring out-of-court settlement options for the cases described in order to minimize expenses and enable it to concentrate on its core business without the costs and distractions imposed by litigations.

The shareholder CIA Consultancy Hamburg has taken legal action at the regional court Gera against the resolutions concerning Top 4 and Top 6 of the annual general meeting at November 18th, 2008.

The company believes that this case is without merit and intends to vigorously defend its position.

#### **Important events after the end of the first 9 months of 2008/2009**

No important events are to be reported

## **Outlook**

The statements made in the “Outlook” section are based on the operative planning of the biolitec group for the years 2008/2009 through 2009/2010.

The continuing economic crisis has increased the risk of a worldwide recession and deflation. In the light of the current environment, forecasts are connected with a high degree of uncertainty.

biolitec’s operations focus on the global growth markets minimally invasive surgery as well as aesthetics. The demographic development as well as the cost and workload pressure on patients as well as physicians and hospitals will lead to a continuously increasing demand for our minimally invasive products. The company expects that the general downward trend on the international capital markets, the economic weakness of the US and the effects of the financial crisis on the global economy as well as the global banking system crisis will be resolved by appropriate measures of the governments of the leading industrial nations.

biolitec expects sales growth from the low levels seen in the coming quarters and plans to take further appropriate cost containment measures where we perceive them as necessary. The main sales growth should arise from equipment and disposables (catheter, laser fibers) for the BPH treatment as well as for the ELVeS™ vein treatment method. In addition, revenue is expected to increase due to newly developed markets (Mid-East, etc.) as well as due to the new hemorrhoid treatment.

The research and development efforts will remain at a high level in order to attain sustainable long-term results. But the contributions from the pharma companies will help to reduce the financial burden in the future.

At this time, we plan no acquisitions. However, we remain open to act on opportunities.

**Consolidated balance sheet according to IFRS  
For the period from July 1, 2008 to March 31, 2009**

	9-months Report 9-Monatsbericht 31.03.2009 €	Annual Report Jahresabschluss 30.06.2008 €
<b>Assets</b>		
<b>Non-current assets</b>		
<b>Intangible assets:</b>	<b>8.325.999</b>	<b>8.003.506</b>
Goodwill	4.123.783	4.123.783
Concessions, intellectual property rights and licenses	4.202.216	3.879.723
<b>Property, plant and equipment:</b>	<b>7.890.304</b>	<b>7.950.181</b>
Land and buildings	1.723.477	1.775.106
Machinery and technical equipment	2.552.452	2.580.469
Other operating and office equipment	2.961.385	2.975.197
Payments on accounts and tangible assets under construction	652.990	619.409
<b>Financial assets:</b>	<b>1.049.431</b>	<b>715.324</b>
Investments	66.020	25.565
Other loans	983.411	689.759
<b>Deferred taxes</b>	<b>3.990.672</b>	<b>2.551.834</b>
<b>Total non-current assets</b>	<b>21.256.406</b>	<b>19.220.845</b>
<b>Current assets</b>		
<b>Inventories:</b>	<b>25.722.171</b>	<b>24.066.539</b>
Raw materials and supplies	5.626.500	5.761.063
Work in progress	526.090	737.143
Finished goods and goods for resale	19.569.581	17.568.333
<b>Accounts and other properties</b>	<b>13.463.231</b>	<b>13.118.524</b>
Trade accounts receivable	9.964.071	10.844.291
Other current assets	3.499.160	2.274.233
<b>Cash and cash equivalents</b>	<b>5.057.572</b>	<b>10.243.150</b>
<b>Total current assets</b>	<b>44.242.974</b>	<b>47.428.213</b>
<b>Total assets</b>	<b>65.499.380</b>	<b>66.649.058</b>

**Consolidated balance sheet according to IFRS**  
**For the period from July 1, 2008 to March 31, 2009**

	9-months Report 9-Monatsbericht 31.03.2009	Annual Report Jahresabschluss 30.06.2008
	€	€
<b>Liabilities and shareholders equity</b>		
<b>Shareholders equity</b>		
Share Capital	10.515.750	10.515.750
Additional paid-in capital	34.113.216	34.113.216
Legal reserves	141	141
Retained earnings	5.378.669	5.518.502
Adjustment item for foreign currency exchange rates	1.435.208	-387.984
Additional fair value	2.532.733	2.532.733
<b>Total shareholders' equity</b>	<b>53.975.717</b>	<b>52.292.358</b>
Minority interest	-17.240	209.052
<b>Non-current liabilities</b>		
Financial liabilities	5.852.234	4.720.662
Deferred tax liabilities	157.354	146.872
<b>Total non-current liabilities</b>	<b>6.009.588</b>	<b>4.867.534</b>
<b>Current Liabilities</b>		
Financial liabilities	912.330	2.492.086
Trade accounts payable	1.967.789	3.986.428
Advance payments received	7.689	21.948
Other liabilities	103.696	168.550
<b>Accrued expenses:</b>	<b>2.539.811</b>	<b>2.611.102</b>
Tax accruals	352.180	494.962
Other accrued expenses	2.187.631	2.116.140
<b>Total current liabilities</b>	<b>5.531.315</b>	<b>9.280.114</b>
<b>Total liabilities and shareholders' equity</b>	<b>65.499.380</b>	<b>66.649.058</b>

**Consolidated income statement according to IFRS**  
**For the period from July 1, 2008 to March 31, 2009**

<b>Income Statement</b>	<b>9 Months Report</b>	<b>9 Months Report</b>
	<b>9 Monatsbericht</b>	<b>9 Monatsbericht</b>
	<b>01.07.2008 - 31.03.2009</b>	<b>01.07.2007 - 31.03.2008</b>
	<b>€</b>	<b>€</b>
<b>Revenues</b>	<b>23.278.352</b>	<b>28.045.296</b>
Cost of revenues	-7.120.313	-8.646.102
<b>Gross profit</b>	<b>16.158.039</b>	<b>19.399.194</b>
Other operating income	1.618.728	1.197.059
Selling and marketing expenses	-10.061.368	-7.601.139
General administrative expenses	-4.512.160	-5.105.693
Research and development expenses	-3.492.212	-3.614.238
Other operating expenses	-339.731	-50.102
<b>Operating income</b>	<b>-628.704</b>	<b>4.225.082</b>
Other income	-32.807	380.692
Foreign currency exchange losses	-12.026	-359.266
Other taxes	-27.490	-14.783
<b>Result before interest and income tax - EBIT</b>	<b>-701.027</b>	<b>4.231.725</b>
Interest Income and Expense	-148.024	40.407
Income tax	709.218	-751.110
<b>Result before minority interest</b>	<b>-139.833</b>	<b>3.521.022</b>
Minority interest	-226.292	-195.208
<b>Net Income / Loss</b>	<b>-366.125</b>	<b>3.325.814</b>
Accumulated income / loss brought forward	5.518.502	4.218.017
Changes in Reserve	0	-789.790
<b>Retained earnings (before minority interest)</b>	<b>5.378.669</b>	<b>6.754.041</b>
Earnings per share (basic)	-0,03	0,32
Earnings per share (diluted)	-0,03	0,32
Weighted average shares outstanding (basic)	10.515.750	10.515.750
Weighted average shares outstanding (diluted)	10.515.750	10.540.750

**Consolidated income statement according to IFRS**  
**For the period from January 1, 2009 to March 31, 2009**

<b>Income Statement</b>	<b>3rd Quarter</b>	<b>3rd Quarter</b>
	<b>3. Quartal</b>	<b>3. Quartal</b>
	<b>01.01.2009 - 31.03.2009</b>	<b>01.01.2008 - 31.03.2008</b>
	<b>TEuro</b>	<b>TEuro</b>
<b>Revenues</b>	<b>7.821.167</b>	<b>8.912.875</b>
Cost of revenues	-1.822.097	-2.559.012
<b>Gross profit</b>	<b>5.999.070</b>	<b>6.353.863</b>
Other operating income	497.830	200.596
Selling and marketing expenses	-3.769.903	-2.284.483
General and administrative expenses	-1.595.570	-2.568.148
Research and development expenses	-889.490	-427.360
Other operating expenses	-289.920	40.792
<b>Operating income</b>	<b>-47.983</b>	<b>1.315.261</b>
Other income and expenses	-29	99.986
Other income / expenses	0	0
Foreign currency exchange gains / losses	-39.371	-216.844
Other taxes	-17.354	-3.138
<b>Result before interest and income tax - EBIT</b>	<b>-104.737</b>	<b>1.195.265</b>
Interest Income and Expense	-114.123	19.501
Income tax / Deferred taxes	-16.166	21.661
<b>Result before minority interest</b>	<b>-235.026</b>	<b>1.236.427</b>
Minority interest	38.403	-145.324
IFRS Adjustment	0	0
<b>Net Income / Loss</b>	<b>-196.623</b>	<b>1.091.103</b>

**Consolidated Cash flow statement according to IFRS**  
**For the period from July 1, 2008 to March 31, 2009**

<b>Cash Flow Statement</b>	<b>9 Months Report</b>	<b>9 Months Report</b>
	<b>9 Monatsbericht</b>	<b>9 Monatsbericht</b>
	<b>01.07.2008 - 31.03.2009</b>	<b>01.07.2008 - 31.03.2008</b>
	<b>T €</b>	<b>T €</b>
	<b>IFRS</b>	<b>IFRS</b>
<b>Cash flow from operating activities</b>		
Consolidated net income before interest/minority interest	8	2.439
Adjustments for:		
Minority Interest	-226	-195
Depreciation and Amortization of fixed assets	1.423	1.432
Earnings for asset disposal		
Financial result		
Provisions and value adjustments	179	-1.936
Income taxes / Deferred taxes	993	0
Assets not attributable to investing or financing activities	0	0
Trade accounts payable and other assets not attributable to investing or financing activities	-2.019	166
Change in net working capital	-3.574	-4.618
Other Adjustments		-40
<b>Net Cash used for operating activities</b>	<b>-3.216</b>	<b>-2.752</b>
<b>Cash flow from investing activities</b>		
Additions of property, plant and equipment	-998	-1.608
Additions of intangible assets	-375	-74
Additions to financial assets		-58
Payments from disposal of noncurrent assets		
<b>Net cash from/used in investing activities</b>	<b>-1.373</b>	<b>-1.740</b>
<b>Cash flow from financing activities</b>		
Proceeds from short or long-term borrowings	0	4.496
Cash repayments of amounts borrowed	-448	0
Change in other comprehensive income	0	
Paid-in additions in capital		6.731
Returns on interest	167	115
Interest payments	-315	-75
Others		
<b>Net cash from / used in financing activities</b>	<b>-596</b>	<b>11.267</b>
Change in cash and cash equivalents	-5.185	6.775
<b>Cash and cash equivalents at beginning of period</b>	<b>10.243</b>	<b>4.262</b>
<b>Cash and cash equivalents at end of period</b>	<b>5.058</b>	<b>11.037</b>

## Consolidated statement of changes in equity according to IFRS for the fiscal year from July 1, 2008 to March 31, 2009

	Share Capital €	Additional paid-in capital €	Additional fair value €	Retained earnings / accumulated deficit €	Unrealised profit of financial instruments €	Other comprehensive income €	Shareholders equity before minority interest €	Minority interest €	Consolidated shareholder's equity €
<b>01.07.2007</b>	<b>10.015.000</b>	<b>27.784.241</b>	<b>2.532.733</b>	<b>3.538.742</b>	<b>0</b>	<b>64.841</b>	<b>43.935.557</b>	<b>263.752</b>	<b>44.199.309</b>
Capital Additions	500.750	6.230.039					<b>6.730.789</b>		6.730.789
Consolidated net income			-691.908	3.170.059			<b>2.478.151</b>	0	2.478.151
Currency translation						-872.016	<b>-872.016</b>	195.205	-676.811
Appropriation of net retained profits							<b>0</b>		0
<b>31.03.2008</b>	<b>10.515.750</b>	<b>34.014.280</b>	<b>1.840.825</b>	<b>6.708.801</b>	<b>0</b>	<b>-807.175</b>	<b>52.272.481</b>	<b>458.957</b>	<b>52.731.438</b>
<b>01.07.2008</b>	<b>10.515.750</b>	<b>34.113.357</b>	<b>2.532.733</b>	<b>5.518.502</b>	<b>0</b>	<b>-387.984</b>	<b>52.292.358</b>	<b>209.052</b>	<b>52.501.410</b>
Consolidated net income			0	-139.833			<b>-139.833</b>	-226.292	-366.125
Currency translation						1.823.192	<b>1.823.192</b>	0	1.823.192
Appropriation of net retained profits							<b>0</b>		0
<b>31.03.2009</b>	<b>10.515.750</b>	<b>34.113.357</b>	<b>2.532.733</b>	<b>5.378.669</b>	<b>0</b>	<b>1.435.208</b>	<b>53.975.717</b>	<b>-17.240</b>	<b>53.958.477</b>

## **NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FISCAL YEAR FROM JULY 1, 2008, TO MARCH 31, 2009**

### **General**

The applied accounting principles and valuation standards as well as calculation methods are in accordance with those used for the annual consolidated financial statements of the fiscal year. Balance sheet items were consolidated at the current exchange rate and income statement items were consolidated at the average exchange rate. Equity items were consolidated at historical exchange rates.

Pursuant to Section 315a of the German Commercial Code, the consolidated interim financial statements as of March 31, 2009 have been prepared according to the International Financial Reporting Standards (IFRS) - including IAS 34 - of the International Accounting Standards Board (IASB), London, which are endorsed by the European Union, and the Interpretations of the International Financial Reporting Interpretations Committee (IFRIC), in effect at the closing date.

The interim financial statements should be read in conjunction with the audited IFRS consolidated financial statements and notes thereto which were published on September 30, 2008 and which were included in biolitec's 2007/2008 Annual Report.

The income statement is not comparable to the published quarters of the report 07/08, since corrections following IFRS 8 (see annual report 2007/2008) had to be made along with the financial statement 07/08, and thus the income statement had to be adapted.

## Segment reporting

The segmentation follows the group's internal organizational and reporting structure. The company has based its segment reporting on the criteria also applied by the group's management for dividing the biolitec group into the units for which it takes decisions and carries out business analyses and assessments. The chosen product-oriented segmentation follows this division.

	Fiber Optics / Laser Probes	Lasers	Pharma	Consolidation
	1.7.2008 – 31.03.2009	1.7.2008 – 31.03.2009	1.7.2008 – 31.03.2009	1.7.2008 – 31.03.2009
	T€	T€	T€	T€
Sales	15.565	6.499	1.214	23.278
Segment result	1.627	-534	-1.233	-140

	Fiber Optics / Laser Probes	Lasers	Pharma	Consolidation
	1.7.2007– 31.03.2008	1.7.2007– 31.03.2008	1.7.2007– 31.03.2008	1.7.2007– 31.03.2008
	T€	T€	T€	T€
Sales	17.300	9.397	1.349	28.046
Segment result	2.132	1.765	-1.407	2.490

## Declaration of Compliance with the German Corporate Governance Code

According to the statement of the German Corporate Governance Code, the members of the Board of Directors and the Supervisory Board of biolitec AG declare that the company has made the prescribed statement according to article 161 AktG. It is permanently published for all shareholders on the company's website, [www.biolitec.de](http://www.biolitec.de).

## Stockholders' Equity

On November 18, 2008, the annual general meeting authorized biolitec to acquire treasury stocks for certain defined purposes up to a maximum amount of 1,051,575 own shares, representing nearly 10 % of the capital stock, before May 17, 2010.

## Director's Dealings

In the first 9 months of the business year 2008/2009 members of the directors board executed securities transactions subject to reporting requirements pursuant to article 15a WpHG.

Datum/ Date	Name	Funktion/ Function	Art der Transaktion/ Type of transaction	Stückzahl/ Number of shares	Kurs/Preis Price Euro	Gesamt- volumen EUR Total volume EUR
11. 11.2008	Dr. Stefan Spaniol	Vorstand/ Board of Directors	Erwerb von Aktien/ Acquisition of shares	2000	3,00 3.00	6.000 6,000
17. 11.2008	Dr. Stefan Spaniol	Vorstand/ Board of Directors	Erwerb von Aktien/ Acquisition of shares	2000	2,96 2.96	5.920 5,920
18. 11.2008	Dr. Stefan Spaniol	Vorstand/ Board of Directors	Erwerb von Aktien/ Acquisition of shares	500	2,77 2.77	1.385 1,385
19. 11.2008	Dr. Stefan Spaniol	Vorstand/ Board of Directors	Erwerb von Aktien/ Acquisition of shares	600	2,77 2.77	1.662 1,662

## **Auditors Review**

The financial statements as well as this interim report are unreviewed.

## **Related party transactions**

Within the group, business relationships are existing between the biolitec AG and its sales, production and research affiliates for the exchange of goods and services. These supply and performance relationships are transacted at market prices. Specific costs, which biolitec AG has incurred as a result of activities for affiliates, were cross charged to the relevant companies.

## **Declaration by the Executive Board**

To the best of our knowledge, and in accordance with the applied fundamentals of proper corporate reporting, we ensure that the consolidated balance sheet of biolitec AG, dated March 31, 2009, conveys a representation of the asset, financial and earnings situation of the group that corresponds to actual conditions, and that the groups management report illustrates the progression of the business including business results and the condition of the group in such a way that a representation is given which reflects actual conditions, and that the significant opportunities and risks associated with the anticipated development of the group are described.

Jena, May 29, 2009

Dr. Wolfgang Neuberger

## **Notation of the figures**

The figures are rounded.

## Financial Calendar

Annual Report 2008/2009	September 30, 2009
Annual General Meeting 2009 Jena	November 17, 2009
Analyst- and Investor Conference „German Equity Capital Forum, Autumn 2009” Frankfurt am Main, Germany	November 2009

## Investor Relations Contact

### biolitec AG

Winzerlaer Straße 2

07745 Jena

Germany

E-mail        [ir@biolitec.de](mailto:ir@biolitec.de)

Phone        +49 36 41/50 85 54

Fax         +49 36 41/50 85 99

## Imprint

Editor        biolitec AG

Winzerlaer Straße 2

D-07745 Jena

Phone        +49 36 41/50 85 54

Copyright    biolitec AG

Pictures     biolitec AG

The German version is relevant.

## **Addresses of major subsidiaries**

### **Adressen wesentlicher Niederlassungen**

#### **biolitec AG**

Winzerlaer Straße 2

07745 Jena, Germany

Fon: +49 36 41 50 85 50

Fax: +49 36 41 50 85 99

E-Mail: [info@biolitec.de](mailto:info@biolitec.de)

<http://www.biolitec.de>

#### **biolitec Inc.**

515 A Shaker Road

East Longmeadow, MA 01028, USA

Fon: +1 413 5 25 06 00

Fax: +1 413 5 25 06 11

E-Mail: [info@biolitec.com](mailto:info@biolitec.com)

<http://www.biolitec.com>

#### **biolitec Pharma (Ireland) Ltd.**

United Drug House

Magna Drive, Magna Business Park

Citywest Road

Dublin 24, Ireland

Fon: + 353 1 49 40 945

Fax: + 353 1 49 40 946

E-Mail: [general.info@biolitec.com](mailto:general.info@biolitec.com)

<http://www.biolitecpharma.com>

**biolitec (M) Sdn. Bhd.**

No. 18, Jalan PJS. 7/21

Bandar Sunway

46150 Petaling Jaya, Selangor D.E., Malaysia

Fon: +603 56 32 71 28

Fax: +603 56 38 01 28

E-Mail: [info@biolitec.com.my](mailto:info@biolitec.com.my)

<http://www.biolitec.com>

**biolitec, SIA**

Kaniera iela 10a

Riga, LV-1063

Latvia

Fon: + 371 653 43 646

Fax: + 371 653 07 678

E-mail: [info.lv@biolitec.com](mailto:info.lv@biolitec.com)

<http://www.biolitec.com>

Production:

Domes iela 1a

Livani, LV-5316

Latvia

**biolitec Italia SRL**

Viale Monza 133

20123 Milano, Italy

Fon: +39 02 28 17 2 400

Fax: +39 02 28 17 2 299

E-Mail: [info@biolitec.it](mailto:info@biolitec.it)  
<http://www.biolitec.com>

**CeramOptec GmbH**

Siemensstraße 44  
53121 Bonn, Germany  
Fon: +49 228 97 96 70  
Fax: +49 228 97 96 799  
E-Mail: [info@ceramoptec.de](mailto:info@ceramoptec.de)  
<http://www.ceramoptec.de>

**CeramOptec Industries Inc.**

515 A Shaker Road  
East Longmeadow, MA 01028, USA  
Fon: +1 413 5 25 06 00  
Fax: +1 413 5 25 06 11  
E-Mail: [info@ceramoptec.com](mailto:info@ceramoptec.com)  
<http://www.ceramoptec.com>